Celcuity Inc. - 8-K Filing
Celcuity Inc. receives FDA approval for REVTORPYK (gedatolisib) as the first pan-PI3K/mTOR inhibitor for HR+/HER2-, PIK3CA wild-type locally advanced or metastatic breast cancer.
Tickers: $CELC
More Regulatory news
- Carter Bankshares, Inc. - 8-K Filing
- Marvell Technology, Inc. - 8-K Filing
- VISHAY INTERTECHNOLOGY INC - 8-K Filing
- LATTICE SEMICONDUCTOR CORP - 4 Filing
- CENTRUS ENERGY CORP - 8-K Filing
- SAGA COMMUNICATIONS INC - 8-K Filing
- NextBoat Inc. - 8-K Filing
- CIVISTA BANCSHARES, INC. - 8-K Filing
- RF Acquisition Corp II - 10-Q Filing
- ORASURE TECHNOLOGIES INC - 10-Q Filing